SER Company Profile and Key Details

Serina Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 33.3%. Wall Street analysts project EPS growth of 2.49% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $8.00. The high target offers 205.34% upside. The low target suggests 205.34% downside. The mean target is $8.00. This offers 205.34% upside. Serina Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 17.95%. The prior quarter beat by 31.82%. Over the last six quarters, Apple has recorded several small beats. These include 83.33% in August 11, 2025.

SER has shown mixed momentum, gaining 16.19% over the past week and -40.31% over the past quarter, though year-to-date performance is up 50.03%. Short-term trend indicators are bullishly aligned (SMA20 -16.18%, SMA50 -25.13%, SMA200 -59.25%). The stock’s 14-day RSI is 40.43 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.15% below its high and over 17.98% above its low. Average 10-day trading volume of 33.55 thousand shares is below the 3-month average of 77.27 thousand, indicating normal recent market interest.

Serina Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.28. This means the shares are trading above this model’s fair value.

Serina Therapeutics, Inc. has 15.00 million shares outstanding. The public float is 8.41 million shares, elevated short interest at 2.47% of float. This equals 284.55 thousand shares. The short ratio is 4.05 days. Institutional investors hold 11.27% of the float. Insiders own 50.75%. Bailey Gregory holds 67.24 thousand shares, MINTZ STEVEN has 17.44 thousand shares and Marshall Richard Peter has 12.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 45.50 thousand shares across 2 transactions.

Serina Therapeutics, Inc. (AMEX:SER) closed at $2.62 USD, gaining $0.12 (4.80%) from the previous close of $2.50. The stock is currently mid-range between its 52-week high and low $1.22 and $5.83. With a market capitalization of about $39.29 million, Serina Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.03). Key stats such as the average daily volume over the past year has been around 78.00 thousand shares, in line with its 52-week average. Headquartered in Huntsville, AL, Serina Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven A. Ledger, the company employs approximately 16 people and listed since November 28, 2018. Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain.

Serina Therapeutics, Inc. trades at a P/E ratio of -1.39, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.28 suggesting the stock is closer to book value. The P/FCF stands at -1.85, also above market averages.

Our AI price prediction model suggests that Serina Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.02%, with price expected at $2.83 by September 16, 2026, within a range of $2.59 to $3.08 3-Month Outlook: Projected fall of -14.5%, reaching $2.24 by December 01, 2026, with a range of $2.03 to $2.43. 1-Year Outlook: Projected loss of -56.11%, with price at $1.15 by September 02, 2027, within a range of $0.74 to $1.56.

Serina Therapeutics, Inc. (AMEX:SER) shares are up 50.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Serina Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.39. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.25, suggesting 367.56% upside. Our AI forecast model points to short-term strength (8.02% over two weeks), a medium-term fall (-14.5% over three months), and a longer-term loss (-56.11% over one year), with expected trading ranges indicating moderate volatility.